Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy

被引：0

作者：

Berton, Guillaume ^{[1
]}

Arcani, Robin ^{[2
,3
]}

Tichadou, Antoine ^{[1
,4
,5
]}

Farnault, Laure ^{[1
]}

Roche, Pauline ^{[1
]}

Colle, Julien ^{[1
,4
,5
]}

Ivanov, Vadim ^{[1
]}

Mercier, Cedric ^{[1
]}

Couderc, Anne-Laure ^{[6
]}

Costello, Regis ^{[1
,4
,5
]}

Taieb, David ^{[7
]}

Venton, Geoffroy ^{[1
,4
,5
]}

机构：

[1] La Conception Univ Hosp Marseille, Hematol & Cellular Therapy Dept, Marseille, France

[2] CHU La Timone, Assistance Publ Hop Marseille AP HM, Internal Med & Therapeut Dept, Marseille, France

[3] Aix Marseille Univ, Ctr Cardiovasc & Nutr Res C2VN, Marseille, France

[4] Aix Marseille Univ, TAGC, INSERM, UMR1090, Marseille, France

[5] Aix Marseille Univ, SMARTc Unit, Pharmacokinet Lab, Marseille, France

[6] CHU St Marguer, Assistance Publ Hop Marseille AP HM, Geriatr & Therapeut Unit, Internal Med, Marseille, France

[7] Aix Marseille Univ, La Timone Univ Hosp, Dept Nucl Med, CERIMED, Marseille, France

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 07期

关键词：

Secondary acute myeloid leukemia; overall survival; daunorubicin; cytarabine; Haploidentical allogeneic stem cells transplantation; HIGH-RISK; SECONDARY; LEUKEMIA; LU-177-DOTATATE; CHEMOTHERAPY; DIAGNOSIS; ADULTS; PRRT;

D O I：

10.1080/10428194.2023.2199896

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1355 / 1357

页数：3

共 10 条

[1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[2] Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors [J].

Bergsma, Hendrik ;

van Lom, Kirsten ;

Raaijmakers, Marc H. G. P. ;

Konijnenberg, M. ;

Kam, B. L. Boen L. R. ;

Teunissen, Jaap J. M. ;

de Herder, Wouter W. ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) :452-458

[3] Myeloid neoplasms after chemotherapy and PRRT: myth and reality [J].

Bodei, Lisa ;

Modlin, Irvin M. ;

Luster, Markus ;

Forrer, Flavio ;

Cremonesi, Marta ;

Hicks, Rodney J. ;

Ezziddin, Samer ;

Kidd, Mark ;

Chiti, Arturo .

[4] High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy [J].

Brieau, Bertrand ;

Hentic, Olivia ;

Lebtahi, Rachida ;

Palazzo, Maxime ;

Ben Reguiga, Makrem ;

Rebours, Vinciane ;

Maire, Frederique ;

Hammel, Pascal ;

Ruszniewski, Philippe ;

Fenaux, Pierre .

[5] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[6] Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series [J].

Goncalves, Isaac ;

Burbury, Kate ;

Michael, Michael ;

Iravani, Amir ;

Ravi Kumar, Aravind S. ;

Akhurst, Tim ;

Tiong, Ing S. ;

Blombery, Piers ;

Hofman, Michael S. ;

Westerman, David ;

Hicks, Rodney J. ;

Kong, Grace .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (09) :1902-1910

[7]

Lancet JE, 2021, LANCET HAEMATOL, V8, pE481, DOI 10.1016/S2352-3026(21)00134-4

[8] Challenges in the diagnosis and treatment of secondary acute myeloid leukemia [J].

Ossenkoppele, Gert ;

Montesinos, Pau .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 138 :6-13

[9] Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study [J].

Ostgard, Lene Sofie Granfeldt ;

Medeiros, Bruno C. ;

Sengelov, Henrik ;

Norgaard, Mette ;

Andersen, Mette Klarskov ;

Dufva, Inge Hogh ;

Friis, Lone Smidstrup ;

Kjeldsen, Eigil ;

Marcher, Claus Werenberg ;

Preiss, Birgitte ;

Severinsen, Marianne ;

Norgaard, Jan Maxwell .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3641-+

[10] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [J].

Strosberg, J. ;

El-Haddad, G. ;

Wolin, E. ;

Hendifar, A. ;

Yao, J. ;

Chasen, B. ;

Mittra, E. ;

Kunz, P. L. ;

Kulke, M. H. ;

Jacene, H. ;

Bushnell, D. ;

O'Dorisio, T. M. ;

Baum, R. P. ;

Kulkarni, H. R. ;

Caplin, M. ;

Lebtahi, R. ;

Hobday, T. ;

Delpassand, E. ;

Van Cutsem, E. ;

Benson, A. ;

Srirajaskanthan, R. ;

Pavel, M. ;

Mora, J. ;

Berlin, J. ;

Grande, E. ;

Reed, N. ;

Seregni, E. ;

Oberg, K. ;

Sierra, M. Lopera ;

Santoro, P. ;

Thevenet, T. ;

Erion, J. L. ;

Ruszniewski, P. ;

Kwekkeboom, D. ;

Krenning, E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (02) :125-135

← 1 →